Papillary lesions of the breast should be surgically excised to avoid missing a cancer

Key points
- Certain breast lesions diagnosed as benign on core needle biopsy have cancer at surgical excision and thus should be removed, according to a study appearing in the March issue of Radiology.
- "Our study shows that all papillary lesions of the breast should be surgically excised to avoid missing a cancer," said the study's lead author, Cecilia L.
- Papillary lesions are benign growths in the duct of the breast.
- "To date, the management of benign papillary lesions on core needle biopsy has been controversial and may be based on anecdotal evidence or small published studies," Dr.
Certain breast lesions diagnosed as benign on core needle biopsy have cancer at surgical excision and thus should be removed, according to a study appearing in the March issue of Radiology.
"Our study shows that all papillary lesions of the breast should be surgically excised to avoid missing a cancer," said the study's lead author, Cecilia L. Mercado, M.D., assistant professor of radiology at New York University Medical Center in New York City.
Papillary lesions are benign growths in the duct of the breast. They comprise approximately 1 to 3 percent of all lesions sampled by core needle biopsies. Currently, the treatment of these lesions alternates between radiographic follow-up and surgical excision, and is often dependent upon physician recommendation.
"To date, the management of benign papillary lesions on core needle biopsy has been controversial and may be based on anecdotal evidence or small published studies," Dr. Mercado said. "No definite guidelines are published for management of these lesions."
While papillary lesions may be diagnosed as benign, they can harbor adjacent atypical ductal hyperplasia (ADH) - a condition characterized by cells of unusual size, shape, and number in the lining of the milk ducts - and ductal carcinoma in situ (DCIS), which are cancerous cells confined to the lining of the milk ducts. Left unchecked, both these conditions pose increased risk of future malignancy.
For the study, Dr. Mercado and colleagues reviewed the imaging and histologic follow-up findings in 42 patients diagnosed with benign papillary lesions after breast core needle biopsy. Forty-three biopsies were performed on the 42 patients. Of the 43 biopsies, 36 (84 percent) of the lesions were surgically removed, and seven (16 percent) received long-term imaging follow-up.
Upon surgical excision and follow-up, the diagnoses of nine of 42 patients (21.4 percent) were upgraded to ADH or DCIS. This is a much higher percentage than reported by previous studies.
"This is one of the largest series and shows statistically significant findings," Dr. Mercado said. "The results of our study revealed a considerable upgrade rate to either ADH or DCIS at core-needle biopsy. Therefore, all benign papillary lesions of the breast should be surgically excised, since a considerable number of atypical lesions and malignant lesions could be missed."
http://www.rsna.org
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsHigh fruit intake during adolescence linked with lower breast cancer risk
Two linked papers in The BMJ this week shed new light on the relation of alcohol and diet with breast cancer and heart disease . The first study reports that high fruit consumption during adolescence may be associated…
13 May 2016
NewsAndrei Goga's UCSF team finds new approaches to eradicate aggressive breast cancers
Conventional chemotherapy generally fails to eradicate aggressive breast cancers due to the early distant metastasis that can occur in these diseases. Triple-negative breast cancer (TNBC) is a particularly aggressive…
12 May 2016
NewsNovel gene variants identified in male breast cancer
Male breast cancer (MBC) is a very rare tumor type, occurring in just 1% of all breast cancer cases, and the underlying genetic causes and treatment of MBC is not well understood. In a paper published in the March issue…
3 March 2016





